Urol. praxi. 2023;24(3):126-130 | DOI: 10.36290/uro.2023.058

PARP inhibitors in treating metastatic castration-resistant prostate cancer

MUDr. Igor Richter, Ph.D.1, 2, 4, doc. MUDr. Josef Dvořák, Ph.D.2, MUDr. Vladimír Šámal, Ph.D.3, MUDr. Jiří Bartoš, MBA1, MUDr. Sofya Al-Samsam1
1 Onkologické oddělení, Krajská nemocnice Liberec, a. s.
2 Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
3 Urologické oddělení, Krajská nemocnice Liberec, a. s.
4 Technická univerzita Liberec, Fakulta zdravotnických studií, Liberec

Several different types of systemic therapy are available for the treatment of metastatic castration-resistant prostate cancer. The more lines of therapy are used, the more patients' lives can be prolonged. However, despite receiving treatment, patients gradually develop disease progression. Therefore, other treatment modalities are being sought that would prolong the survival of patients with metastatic castration-resistant prostate cancer. PARP (poly(ADP-ribose)polymerase) inhibitors have been shown to be effective in these patients both in monotherapy and in combination with ARTA therapy. The most recent data have been available for the olaparib PARP inhibitor.

Keywords: castration-resistant prostate cancer, metastases, PARP inhibitors, olaparib, talazoparib.

Accepted: September 25, 2023; Published: October 2, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Richter I, Dvořák J, Šámal V, Bartoš J, Al-Samsam S. PARP inhibitors in treating metastatic castration-resistant prostate cancer. Urol. praxi. 2023;24(3):126-130. doi: 10.36290/uro.2023.058.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [Internet]. Masarykova univerzita [2005]. Available from: http://www.svod.cz. Verze 7.0 [2007].
    2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. Go to original source... Go to PubMed...
    3. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostatae cancer progressing after docetaxel treatment: a randimised open-label trial. Lancet. 2010;376:1147-1154. Go to original source... Go to PubMed...
    4. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223. Go to original source... Go to PubMed...
    5. de Bono JS, Logothesis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005. Go to original source... Go to PubMed...
    6. Ryan CJ, Smith MR, de Bono JS, et al. Abirateron in metastatic prostatae cancer without previous chemotherapy. N Engl J Med. 2013;368:138-148. Go to original source... Go to PubMed...
    7. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197. Go to original source... Go to PubMed...
    8. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-433. Go to original source... Go to PubMed...
    9. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. NEJM. 2016;375:443-453. Go to original source... Go to PubMed...
    10. Richter I, Dvořák J, Šámal V, et al. PARP inhibitory v léčbě karcinomu prostaty. Profi Medicína. 2023;2:27-28.
    11. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. NEJM. 2016;375:443-453. Go to original source... Go to PubMed...
    12. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. NEJM. 2017;377:523-533. Go to original source... Go to PubMed...
    13. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM. 2020;382:2091-2102. Go to original source... Go to PubMed...
    14. de Bono JS, Mehra N, Scagliotti GV, et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 2021;22:1250-1264. Erratum in: Lancet Oncol. 2022; 23:e207. Erratum in: Lancet Oncol. 2022;23:e249 Go to original source... Go to PubMed...
    15. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM. 2022;1(9). Go to original source... Go to PubMed...
    16. Clarke NW. Presented at ASCO GU 2023. 16-18 February. San Francisco, US. Abstract #LBA16.
    17. Agarwal N, Azad A, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. The Lancet. 2023;402:291-303. Go to original source... Go to PubMed...
    18. Chi KN, Rathkopf D, Smith MR, et al. Niraparib and abirateron acetate for metastatic castration-resistant prostate cancer. JCO 2023;41:3339-3351. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.